Drug Classes
Ramipril is an angiotensin-converting enzyme inhibitor (ACE inhibitor), and amlodipine is a dihydropyridine calcium channel blocker (CCB). 1, 2, 3
Ramipril - ACE Inhibitor
Ramipril belongs to the ACE inhibitor class of antihypertensive medications. It is a prodrug that is converted to its active metabolite, ramiprilat, through hepatic cleavage of the ester group 3. As an ACE inhibitor, ramipril works by blocking the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion.
Key characteristics:
- Mechanism: Non-sulfhydryl ACE inhibitor (via active metabolite ramiprilat) 3
- Dosing: Typically 2.5-10 mg daily for hypertension 1, 3
- Clinical applications: Hypertension, heart failure post-myocardial infarction, cardiovascular risk reduction 1, 4, 3
Ramipril is consistently listed among the most prescribed antihypertensive medications globally, ranking second in the UK (17% of prescriptions) and second in the EU (15.9% of prescriptions) 2.
Amlodipine - Dihydropyridine Calcium Channel Blocker
Amlodipine is classified as a dihydropyridine calcium channel blocker 5, 6. This subclass distinction is clinically important because dihydropyridines have high selectivity for vascular smooth muscle with minimal effects on myocardial contractility or cardiac conduction 6.
Key characteristics:
- Mechanism: Potent peripheral and coronary vasodilator with vascular selectivity 6
- Pharmacokinetics: Long half-life of 36-45 hours, allowing once-daily dosing 6
- Dosing: Typically 5-10 mg daily 1, 7
- Clinical applications: Hypertension, chronic stable angina, vasospastic angina 6
Amlodipine ranks first in UK prescriptions (17.0%) and third in EU prescriptions (10.2%) for hypertension 2.
Clinical Significance of the Combination
The combination of ramipril (ACE inhibitor) and amlodipine (dihydropyridine CCB) is frequently used together, as these drug classes act synergistically to reduce blood pressure through complementary mechanisms 8, 9. Fixed-dose combinations of ramipril/amlodipine have demonstrated superior blood pressure control compared to monotherapy 8 and improved medication persistence compared to free-equivalent combinations 10, 11.
Important distinction: The 2023 AACE guidelines specifically note that dihydropyridine calcium channel blockers (like amlodipine) should be preferred over non-dihydropyridine agents (like verapamil or diltiazem) in most hypertensive patients 5.